Metastatic triple-negative breast cancer
Clinical trials for Metastatic triple-negative breast cancer explained in plain language.
Never miss a new study
Get alerted when new Metastatic triple-negative breast cancer trials appear
Sign up with your email to follow new studies for Metastatic triple-negative breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shows promise in Tough-to-Treat breast cancer
Disease control CompletedThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin) helps people with metastatic triple-negative breast cancer live longer without their disease getting worse. About 78 participants with advanced cancer that has spread will rece…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Old arthritis drug shows promise against aggressive breast cancer
Disease control CompletedThis study tested leflunomide, a pill usually used for arthritis, in 17 women with metastatic triple negative breast cancer (a fast-growing type). The goal was to see if it is safe and can help control the cancer. The drug works by blocking a protein the cancer needs to grow.
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase 1/2 • Sponsor: Joseph Sparano • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo shows promise for tough breast cancer
Disease control CompletedThis pilot study tested a combination of two drugs, veliparib and lapatinib, in 20 people with metastatic triple negative breast cancer that had already been treated. The main goal was to see how safe the combination is and how many patients respond. All participants received the…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC